There Is Clear Momentum For X4 Pharmaceuticals Inc (NASDAQ: XFOR)

X4 Pharmaceuticals Inc (XFOR) concluded trading on Wednesday at a closing price of $1.47, with 4.65 million shares of worth about $6.83 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 48.60% during that period and on April 3, 2024 the price saw a gain of about 6.52%. Currently the company’s common shares owned by public are about 167.43M shares, out of which, 121.91M shares are available for trading.

However, the stock later moved at a day high price of 1.6000, or with a gain of 6.52%. Stock saw a price change of 1.38% in past 5 days and over the past one month there was a price change of 51.02%. Year-to-date (YTD), XFOR shares are showing a performance of 75.31% which increased to 68.97% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.57 but also hit the highest price of $2.58 during that period. The average intraday trading volume for X4 Pharmaceuticals Inc shares is 2.01 million. The stock is currently trading 31.94% above its 20-day simple moving average (SMA20), while that difference is up 50.76% for SMA50 and it goes to 31.35% higher than SMA200.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

X4 Pharmaceuticals Inc (NASDAQ: XFOR) currently have 167.43M outstanding shares and institutions hold larger chunk of about 35.96% of that.

The stock has a current market capitalization of $246.87M and its 3Y-monthly beta is at 0.46. It has posted earnings per share of -$0.60 in the same period. It has Quick Ratio of 5.34 while making debt-to-equity ratio of 1.14. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for XFOR, volatility over the week remained 10.02% while standing at 10.54% over the month.

Analysts are in expectations that X4 Pharmaceuticals Inc (XFOR) stock would likely to be making an EPS of -$0.16 in the current quarter, while forecast for next quarter EPS is -$0.04 and it is -$0.45 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.22 which is -$0.13 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.16 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 20.80% while it is estimated to increase by 0.63% in next year.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by B. Riley Securities on December 12, 2023 offering a Neutral rating for the stock and assigned a target price range of between $3 and $1 to it. Coverage by B. Riley Securities stated X4 Pharmaceuticals Inc (XFOR) stock as a Buy in their note to investors on August 30, 2023, suggesting a price target of $3 for the stock. On December 22, 2022, Cantor Fitzgerald Initiated their recommendations, while on December 12, 2022, Piper Sandler Initiated their ratings for the stock with a price target of $3. Stock get an Outperform rating from Oppenheimer on December 23, 2019.

Most Popular

Related Posts